BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA

Published February 7, 2011

BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
NOVATO, Calif., Feb. 1, 2011 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome. “In under two years, we have progressed the GALNS …
Read more on redOrbit

Helix BioPharma Corp. Receives FDA IND Approval to Conduct a U.S. Phase I Clinical Study With Its Lung Cancer Drug …
AURORA, ON–(Marketwire – February 7, 2011) – Helix BioPharma Corp. ( TSX : HBP ) ( NYSE Amex : HBP ) ( FRANKFURT : HBP ), a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has received approval for its investigational new drug (“IND”) application from the United States Food and Drug Administration (“FDA”) to perform its planned …
Read more on Marketwire

State agency head likens budget cuts to an amputation
By ERIK SCHELZIG Associated Press NASHVILLE (AP) — Commissioner Doug Varney of the Tennessee Department of Mental Health on Wednesday likened pending budget cuts to amputating fingers.
Read more on Union City Messenger